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Abstract
Background: There is increasing interest in naltrexone,
an opiate antagonist, in the treatment of opiate addicts.
The effects of naltrexone are often compromised by a
lack of compliance and drop-out. The effects of this com-
pound are probably more favorable when combined
with a psychosocial intervention such as the Community
Reinforcement Approach (CRA). Aim: To explore the
effects of a combination therapy (naltrexone plus CRA
treatment) and the predictive value of sociodemographic
and psychopathologic characteristics. Method: Using a
before-and-after design, heroine addicts (n = 24) receiv-
ing a combined naltrexone plus CRA treatment are com-
pared with a group (n = 20) on methadone maintenance
therapy (reference group). Results: Over a period of 6
months, 58% (14/24) did not relapse, after 1 year at least
55% (12/22) still met the initial goal of continuous absti-
nence. At baseline, the treatment group and the refer-
ence group were similar on nearly all variables except for
the number of times clients were arrested. Within the
treatment group, a comparison was made between the
continuous abstinent and those who relapsed into fre-
quent opioid use. Differences were significant in the clus-
ter-B personality disorders and in polydrug users. Con-
clusion: The combination of naltrexone plus intensive
CRA in an outpatient setting appears to be promising. A
high score on cluster-B and polydrug use is associated
with relapse.
Copyright © 2003 S. Karger AG, Basel
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Introduction
In the field of opiate addiction treatment, there has
been an increase in the use of pharmacological com-
pounds such as naltrexone. After induction, this agent can
be effective in the prevention of recurrent heroin use.
During naltrexone maintenance treatment, the effects of
heroine will be blocked, leading to lesser anticipation of
the desired effects and a decrease in the relapse rate. Simi-
lar to other forms of therapy aimed at abstinence, patient
compliance is often a problem and many patients relapse
after having discontinued taking medication [1].
One study [2] showed good results with naltrexone
(61% abstinence after 6 months) with highly motivated
participants, such as business people and doctors. In addi-
tion, in southern Europe, good results with naltrexone
(40% abstinence after 6 months treatment) have been
reported [3]. The result is attributed to the traditional
family structure and other forms of social interactions
that increase treatment compliance.
These findings suggest that a combination of naltrex-
one maintenance and psychosocial therapy may lead to an
increase in therapy compliance and a decrease in the
relapse rate.
A promising approach is the Community Reinforce-
ment Approach (CRA) [4]. CRA encompasses elements
such as social network and enhancing motivation and is
often supported by a variety of pharmacological interven-
tions (i.e. naltrexone) and procedures to enhance com-
pliance with the recommended medication regimen.
First, there are interventions aimed at enhancing the
social network (for example interventions including part-
ners and parents, aimed at compliance). CRA pays atten-
tion to the expectations, motivation, coping skills, social,
labor and recreational elements.
However, combined forms of therapy also suffer often
from early dropout and lack of therapy compliance. An
important factor which effects compliance and dropout is
psychiatric comorbidity [5]. In general the severity of psy-
chiatric symptoms worsens the prognoses [6]. Research
suggests that the prevalence of psychiatric disorders
among heroine addicts is high. There is a relationship
between drug addiction and depression, anxiety and per-
sonality disorders [7]. Personality disorders are seen as
negative predictors of treatment outcome [8].
The aim of this open-label study is to optimize the
effects of using a combination of CRA and naltrexone.
The present study consists of a naturalistic follow-up
study with before-and-after comparison without a control
group. In order to assess a possible generalization of the
Table 1. Retention characteristics of the treatment population
Naltrexone plus
CRA population
Number of clients who relapsed 10/24 (42%)
Number of clients who were
abstinent after:
Mean 66 months 14/24 (58%)
Mean 612 months 12/22 (55%)
Mean length of treatment, months 16.6 (SD = 5.3; min 6, max 24)
Mean time to first relapse, months 3.8 (SD = 2.4; min 1, max 7)
Displayed are numbers, percentages, means, standard deviations,
minimal and maximal values.
study, a comparison on relevant variables was made with
a group of heroine addicts participating in a methadone
maintenance program.
The following questions were addressed: (1) is the
study population comparable to the group of addicts par-
ticipating in a methadone maintenance program; (2) what
is the outcome in heroin addicts treated with naltrexone
plus CRA, and (3) what is the predictive value of the
sociodemographic characteristics and psychiatric comor-
bidity in patients treated with naltrexone plus CRA?
Method
Study Population
Treatment Group. The treatment group consist of 24 heroin
addicts treated with naltrexone in a CRA program from February
1996 until evaluation in May 1998. The treatment took place at the
outpatient treatment center for addiction Kentron in Roosendaal
(!100,000), the Netherlands. Subjects were recruited from metha-
done programs through newspaper articles and via addiction clinics
throughout The Netherlands. During the research period 60 persons
showed interest in participating by at least one contact. 24 persons
were included (40%).
All 24 subjects were opiate-dependent and 21 of these were par-
ticipants in a methadone program. Subjects were included during a
24-month period. Table 1 shows that follow-up varied between 6 and
24 months (mean length of treatment 16.6; s.d. 5.3 months).
Detoxification of 19 subjects consisted of a rapid detoxification
procedure [9]. In this procedure naltrexone was administered in
increasing dosage: 12.5 mg/day on day 1, 25 mg/day on day 2, and up
to 50 mg/day on days 3 and 4. To ameliorate withdrawal symptoms,
clonidine, diazepam, midazolam and ondansetron were used as indi-
cated. The other 5 patients were detoxified by a methadone-tapering
procedure either in a regular clinic or at home. Patients from the
latter group had to pay a fee of Eur 227.00 (n = 5), and patients from
the rapid detoxification program had to pay an extra fee of Eur
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1,818.00 (n = 19). Detoxification was followed by naltrexone mainte-
nance. Subjects were stimulated and expected to bring a non-using
partner, spouse or good friend to assist as a coach during detoxifica-
tion and aftercare treatment.
Reference Group. To check selection bias, a reference group of 20
participants randomly drawn from a regular methadone program was
selected.
Intervention
After naltrexone induction, all subjects received a maintenance
dosage of naltrexone of 25 mg/day. The treatment consisted of medi-
cal support, psychosocial interventions followed by a consistent and
strict policy towards compliance (naltrexone) and control of sub-
stance abuse by urine analysis. The importance of the social network
was emphasized. CRA implemented: diagnostic interview (function-
al analysis), psycho-education, pharmacotherapy, compliance thera-
py, urine analyses/monitoring, marriage/relation therapy, and sup-
port of the social network, career orientation, job counseling, educa-
tion and hobbies, problem solving, social skills and cognitive restruc-
turing.
The therapist (first author) has several years experience in the
addiction setting. On regular basis, he received supervision from the
second author and from multidisciplinary coworkers. The CRA pro-
gram was tailored to the work of Meyers and Smith [10]. Treatment
integrity was guarded on the basis of monitoring forms and stored in
files. Data collection, extraction and interviewing was done by an
independent researcher.
During the first month of treatment, counseling sessions averaged
2–3 sessions of 45 min/week, which was reduced to 1 weekly session
of 45 min after 3–6 months, and, during the last phase, to monthly
sessions. After 9 months the dosage of naltrexone was reduced to
12.5 mg/day. Abstinence was verified by means of controlled urine
analyses.
Assessment Procedure
Subjects in the treatment group were interviewed prior to detoxif-
ication regarding baseline characteristics. The reference group was
assessed in the same way.
Instruments
The following questionnaires and tests were included in this
study: (a) SCL-90 (Symptom Check List) [11]; (b) ABV (Amster-
damse Biografische Vragenlijst) [12]; (c) VKP Questionnaire on Per-
sonality Traits (Vragenlijst kenmerken van de persoonlijkheid) [13],
and (d) the VGIT, the shortened version of the GIT (Groningse Intel-
ligentie Test) [14].
(a) The SCL-90 is a multidimensional self-report on mood and
somatic complaints. This list has been translated into Dutch [15].
There is a relationship between the scales of depression and anxiety
in the SCL-90 and relevant categories in the DSM-III(R) [16]. The
SCL-90 has proven to be a reasonable indicator of the severity of
psychopathology among psychiatric patients [17].
(b) The ABV is a personality questionnaire measuring the dimen-
sions: N = neurotic instability; NS = neurotic somatic complaints;
E = social extravertism, and T = test attitude. The T dimension
ranges from a self-criticizing attitude (low score) to a self-defending
attitude (high score) in answering the questionnaire. The N and NS
scales are highly inter-correlated. The test-retest index is satisfactory
[18].
(c) For the presence and severity of personality pathology the
VKP was used. This self-reporting questionnaire is based on the
International Personality Disorder Examination (IPDE) of the WHO
[19]. The VKP provides severity ratings on all 13 DSM-III-R [20]
personality disorders. An important advantage of the VKP (next to
cost-effectiveness) is the fact that during testing there is no systematic
bias or interview tendencies [21]. Compared to an interview, the
VKP has a high sensitivity and a low specificity.
(d) VGIT: in this study intelligence was tested by using the short
version of the GIT [14] consisting of the 3 subtests: numerical, a card
lay puzzler and a word puzzler. The short version correlates 0.91 with
the complete version (10 subtests) of the GIT. The results can be
translated into an IQ score [18].
Statistical Analysis
To assess the predictive value of psychiatric comorbidity compar-
isons were made between the abstinent and relapsed group concern-
ing sociodemographic background, intelligence, juridical conflict,
psychopathology and personality disorders.
Differences in the means of continuous variables were tested by
using the Student’s t test. ¯2 statistics and Fisher’s exact test (two-
sided) were used to test differences in categorical data. Because of the
small sample size and the explorative nature of the study, the signifi-
cance level was set at p ! 0.05.
Results
Comparison of Treatment Group with Regular
Methadone Clients
Table 2 shows that the 2 groups are similar on all vari-
ables except for the number of times clients were arrested
(96% naltrexone vs. 57% methadone, p ! 0.05).
Treatment Outcomes of the Naltrexone Group
After a 6-month treatment period, 14 of 24 clients were
still abstinent (58%). After 1 year, 12 of 22 were still absti-
nent (55%). One client used heroin incidentally after
detoxification without relapse into frequent opiate abuse.
All 10 clients who relapsed into frequent opiate abuse, did
so within 7 months after the start of treatment (table 1).
Of 11 frequent cocaine users, 9 used cocaine a couple
of times during treatment. One of them had a period of
some weeks of extensive cocaine use. In that scenario the
treatment was intensified and adapted to cocaine use,
which ceased. Three clients who regularly used amphet-
amines ceased using this drug. One of them started taking
drugs again after 5 months in treatment, but ceased using
the substance again after 9 months. Of 8 benzodiazepine
users, 6 stopped their benzodiazepine use. One of them
persisted in irregular use of benzodiazepines, another
slowly decreased his use to a stable maintenance level.
The use of cannabis remained the same for almost all
clients.
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Table 2. Characteristics and
psychopathology among naltrexone-
and methadone population
Population
naltrexone (n = 24)
mean SD
methadone (n = 20)
mean SD
p
Age, years 30.5 6.4 29.9 7.1 NS
Age onset opiate addiction, year 21.7 4.5 23.0 5.3 NS
Duration addiction, years 8.8 6.0 7.0 8.0 NS
Daily amount heroine, g 0.6 0.7 0.8 0.8 NS
Daily amount methadone, mg 24.8 10.6 25.7 9.0 NS
Mean IQ 102 10.6 90 13.5 NS
Poly drug users, % 67 91 NS
Women, % 13 18 NS
Min. once arrested, % 96 57 !0.05
Min. once detention, % 58 43 NS
Min. once suicide attempt, % 35 29 NS
Clients with partner, % 63 57 NS
Clients with occupation, % 43 57 NS
Subscale SCL-90 (n = 24) (n = 16)
Anxiety 15.3 5.5 17.1 6.6 NS
Agoraphobia 8.7 3.0 10.6 4.7 NS
Depression 33.0 12.7 34.9 13.4 NS
Som. complaints 21.6 8.6 22.9 9.0 NS
Insufficiency 16.5 5.1 17.4 6.0 NS
Sensitivity 31.2 11.0 31.6 11.6 NS
Hostility 10.3 3.9 9.3 4.6 NS
Insomnia 6.9 3.3 7.2 3.8 NS
Other 14.3 4.9 14.8 5.6 NS
Total 157.6 47.8 165.8 54.1 NS
Subscale ABV (n = 24) (n = 16)
N 69.5 31.6 55.3 27.8 NS
NS 24.3 9.1 23.3 8.9 NS
E 60.8 16.9 52.3 17.5 NS
T 32.7 7.9 37.3 8.3 NS
Displayed are numbers, percentages, meanscores, standard deviations and significant
levels (p ! 0.05) for subscales and total scores of the SCL-90 and ABV.
Predictive Value of Sociodemographic Characteristics
and Psychiatric Comorbidity
The abstinent (n = 14) and relapsed clients (n = 10)
were compared with regard to sociodemographic back-
ground, intelligence, social integration, juridical conflict,
psychopathology and personality disorders. Of the 43 dif-
ferent comparisons made, only three showed statistical
significance: (1) 90% of the relapse population were poly-
drug users compared to 50% in the abstinence group; (2)
the T score of the ABV showed a small but significant dif-
ference, a highly critical self-evaluation indicates a risk of
relapse, and (3) those who relapsed had a higher total
score on the B-cluster personality disorder measured at a
dimensional level (table 3).
Discussion
The results of this pilot study, 55% drug free for a peri-
od of at least 12 months, are promising considering that
this group of heroine addicts had a long addiction history
and a long-term history of failed attempts to become
abstinent. These results were achieved by rapid detoxifi-
cation and by means of psychosocial outpatient treatment
with naltrexone support. For the interpretation of these
results it is important to investigate the selectivity of the
treatment group. A comparison with a reference group of
methadone patients showed that both groups were simi-
lar. There was no difference as to drug abuse history and
the amount and severity of (comorbid) psychopathology
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Table 3. Personality pathology according to
DSM-III(R) axis II as measured by VKP,
among naltrexone-plus CRA group both in
abstinent- and relapsed population
Disorder Dimension score
abstinent (n = 14)
mean SD
relapsed (n = 10)
mean SD
p
Cluster A 5.2 3.8 5.6 4.7 NS
Schizoid 1.1 1.3 1.2 1.3 NS
Schizotypal 2.1 2.1 2.1 2.3 NS
Paranoid 2.1 1.3 2.3 1.6 NS
Cluster B 9.7* 5.0 15.8* 6.4 !0.05
Borderline 2.4 1.8 3.7 2.1 NS
Antisocial 5.1 2.7 7.1 2.8 NS
Histrionic 0.9 1.4 2.0 2.1 NS
Narcissistic 1.4 1.6 3.0 2.4 NS
Cluster C 7.7 7.0 9.5 7.9 NS
Dependent 1.8 1.9 2.8 2.4 NS
Avoidant 1.8 2.2 1.8 2.4 NS
Obsessive-compulsive 1.9 2.1 2.4 2.3 NS
Passive-aggressive 2.2 2.2 2.5 1.6 NS
Appendix A
Sadistic 0.7 0.7 1.1 1.2 NS
Self-defeating 1.9 1.9 2.7 2.1 NS
Displayed are means, standard deviations and significance levels (p ! 0.05) of the dimen-
sional scores and cluster total scores.
* p ! 0.05.
were not less in the naltrexone group. The only difference
was the fact that the subjects participating in naltrexone
treatment had been arrested more frequently than the
subjects of the regular methadone program.
It is, however, likely that those subjects who applied for
participation in the naltrexone group were more moti-
vated than those participants following regular programs.
Patients, in the treatment group could afford to pay a fee,
or had a person in their network willing to pay for the
treatment. Probably only a limited and selective propor-
tion of heroin addicts maintain good contacts with non-
addicts in order to find a non-drug using partner, spouse
or friend willing to assist as a coach during treatment. In
sum, participants in the naltrexone treatment group were
probably better motivated and integrated in the commu-
nity.
However, this can hardly be used as an objection
against the study results, because motivating subjects is
one of the key elements of treatment as a whole. When the
fee was a problem, or when the patient or the network was
incapable of financing the treatment (objective informa-
tion supporting their claim), there was a possibility of rais-
ing the complete amount of money from a charity founda-
tion, from the municipality or from social benefits as a
gift. Prior to acceptance, potential candidates and their
coaches took part in a couple of informative meetings
where they were motivated and prepared for treatment. It
is the experience of the authors that this preparation prior
to detoxification should not be underestimated.
As to any connection between the type of addict and
success rate, we found that the risk of dropout was greatest
among polydrug users, although even here 7 of the 16
polydrug users (44%) benefited from the treatment. In
addition, cluster-B personality disorder was found to be
an indicator for dropout, but was insufficient to be a con-
traindication for participation [22].
Considering a 55% abstinence rate covering an average
period of 12 months and comparing these results with
other studies we find the results promising. Although it is
tempting to credit the results to the applied intervention
(naltrexone plus CRA), this is not possible until a ran-
domized experimental design is followed.
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